Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression on HER2

    Activity: Talk or presentation › Conference presentation

    Description

    Contributors: Kellokumpu-Lehtinen Pirkko / Tieteelliset esitykset
    Period13 May 2005
    Event titleASCO 41st Annual Meeting
    Event typeOther
    Degree of RecognitionInternational